Vaccine profile of herpes zoster (HZ/su) subunit vaccine.

Abstract:

INTRODUCTION:Herpes zoster (HZ) causes an often severe and painful rash in older people and may be complicated by prolonged pain (postherpetic neuralgia; PHN) and by dissemination in immune-compromised patients. HZ results from reactivation of latent varicella-zoster virus (VZV) infection, often associated with age-related or other causes of decreased T cell immunity. A live attenuated vaccine boosts this immunity and provides partial protection against HZ, but this decreases with age and declines over 8 years. Areas covered: A new HZ subunit (HZ/su) vaccine combines a key surface VZV glycoprotein (E) with a T cell-boosting adjuvant system (AS01B) and is administered by two intramuscular injections two months apart. Expert commentary: HZ/su showed excellent efficacy of ~90% in immunocompetent adults ≥50 and ≥70 years of age, respectively, in the ZOE-50 and ZOE-70 phase III controlled trials. Efficacy was unaffected by advancing age and persisted for >3 years. Approximately 9.5% of subjects had severe, but transient (1-2 days) injection site pain, swelling or redness. Compliance with both vaccine doses was high (95%). The vaccine will have a major impact on HZ management. Phase I-II trials showed safety and immunogenicity in severely immunocompromised patients. Phase III trial results are expected soon.

journal_name

Expert Rev Vaccines

authors

Cunningham AL,Heineman T

doi

10.1080/14760584.2017.1329012

subject

Has Abstract

pub_date

2017-07-01 00:00:00

pages

1-10

issue

7

eissn

1476-0584

issn

1744-8395

journal_volume

16

pub_type

杂志文章,评审
  • Gold nanoparticles and vaccine development.

    abstract::Mucosal vaccines constitute an advantageous immunization approach to achieve broad immunization against widespread diseases; however, improvements in this field are still required to expand their exploitation. As gold nanoparticles are biocompatible and can be easily functionalized with antigens, they have been propos...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.1064772

    authors: Salazar-González JA,González-Ortega O,Rosales-Mendoza S

    更新日期:2015-01-01 00:00:00

  • Plant production systems for vaccines.

    abstract::Plants offer an attractive alternative for the production and delivery of subunit vaccines. Various antigens have been expressed at sufficiently high levels in plants to render vaccine development practical. An increasing body of evidence demonstrates that these plant-produced antigens can induce immunogenic responses...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2.6.763

    authors: Streatfield SJ,Howard JA

    更新日期:2003-12-01 00:00:00

  • Alternative administration routes and delivery technologies for polio vaccines.

    abstract::Global polio eradication is closer than ever. Replacement of the live attenuated oral poliovirus vaccine (OPV) by inactivated poliovirus vaccine (IPV) is recommended to achieve complete eradication. Limited global production capacity and relatively high IPV costs compared to OPV spur the need for improved polio vaccin...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1158650

    authors: Kraan H,van der Stel W,Kersten G,Amorij JP

    更新日期:2016-08-01 00:00:00

  • Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.

    abstract::Conjugate vaccines using diphtheria toxoid variant (CRM(197)), diphtheria toxoid and tetanus toxoid (TT) as carrier protein may induce immune interactions (interference or impairment as measured by lower antibody levels, or enhancement [higher antibody levels]) when coadministered with other vaccines. Immune enhanceme...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.142

    authors: Borrow R,Dagan R,Zepp F,Hallander H,Poolman J

    更新日期:2011-11-01 00:00:00

  • Protein/peptide and DNA vaccine delivery by targeting C-type lectin receptors.

    abstract::C-type lectin receptors (CLRs) are a class of pathogen-recognition receptors that are actively investigated in the field of vaccine delivery. Many of their properties have functions linked to the immune system. These receptors are expressed abundantly on antigen-presenting cells and are considered to be the sentinels ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.7.7.1005

    authors: Tang CK,Sheng KC,Apostolopoulos V,Pietersz GA

    更新日期:2008-09-01 00:00:00

  • Virus-like particles as universal influenza vaccines.

    abstract::Current influenza vaccines are primarily targeted to induce immunity to the influenza virus strain-specific hemagglutinin antigen and are not effective in controlling outbreaks of new pandemic viruses. An approach for developing universal vaccines is to present highly conserved antigenic epitopes in an immunogenic con...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.12.70

    authors: Kang SM,Kim MC,Compans RW

    更新日期:2012-08-01 00:00:00

  • The baboon model of pertussis: effective use and lessons for pertussis vaccines.

    abstract::The USA is experiencing a pertussis resurgence that resulted in a 60-year high of 48,000 cases in 2012. Our ability to counteract this resurgence is hampered by the fact that pertussis pathogenesis and immunity to pertussis infection are not well studied. Studies in humans are difficult due to the low frequency of per...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2014.946016

    authors: Warfel JM,Merkel TJ

    更新日期:2014-10-01 00:00:00

  • Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics.

    abstract:INTRODUCTION:Intranasal influenza vaccines are expected to confer protection among vaccine recipients by successful induction of mucosal immune response in the upper respiratory tract. Though only live attenuated influenza virus vaccines (LAIVs) are licensed and available for intranasal use in humans today, intranasal ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2018.1507743

    authors: Sano K,Ainai A,Suzuki T,Hasegawa H

    更新日期:2018-08-01 00:00:00

  • Development of cowpea mosaic virus-based vectors for the production of vaccines in plants.

    abstract::Plant viruses are emerging as an attractive alternative to stable genetic transformation for the expression of foreign proteins in plants. The main advantages of using this strategy are that viral genomes are small and easy to manipulate, infection of plants with modified viruses is simpler and quicker than the regene...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.4.5.687

    authors: Cañizares MC,Lomonossoff GP,Nicholson L

    更新日期:2005-10-01 00:00:00

  • A call for replicating vector prime-protein boost strategies in HIV vaccine design.

    abstract::A key challenge to HIV vaccine development is the integration of HIV proviral DNA into the host genome upon infection. Therefore, an optimal vaccine should block infection within hours of viral exposure, providing 'sterilizing immunity' at mucosal sites and in blood via potent, broadly reactive antibody to the HIV env...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.3.4.s105

    authors: Malkevitch NV,Robert-Guroff M

    更新日期:2004-08-01 00:00:00

  • Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era.

    abstract::Pneumococcal disease is a major health problem worldwide. Large, rapid declines in overall invasive pneumococcal disease and mucosal disease in children, reductions in vaccine-type disease in unvaccinated children and adults (indirect effects) and significant drops in antibiotic-resistant infections were observed afte...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.7.9.1367

    authors: Dinleyici EC,Yargic ZA

    更新日期:2008-11-01 00:00:00

  • Host immunity to Bacillus anthracis lethal factor and other immunogens: implications for vaccine design.

    abstract::Infections of humans with Bacillus anthracis are an issue with respect to the biothreat both to civilians and military personnel, infections of individuals by infected livestock in endemic regions and, recently, infections of intravenous drug users injecting anthrax-contaminated heroin. Existing vaccination regimens a...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.981533

    authors: Altmann DM

    更新日期:2015-03-01 00:00:00

  • Breast cancer vaccines: current research and future prospects.

    abstract::Although the immune system can clearly recognize cancer cells, there is little evidence that it does so to any effective consequence in patients with advanced breast cancer. The possibility of effective control of micrometastatic disease remains but is unproven. The challenge for the clinician is to find ways to enhan...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.1.1.29

    authors: Cameron DA

    更新日期:2002-06-01 00:00:00

  • 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix.

    abstract::The global burden of disease due to Streptococcus pneumoniae remains high. The licensed 7-valent pneumococcal conjugate vaccine (7vCRM, Prevenar/Prevnar) has successfully reduced invasive disease in the USA, but serotype coverage is incomplete and some evidence suggests that serotype replacement has occurred. Recently...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.09.113

    authors: Prymula R,Schuerman L

    更新日期:2009-11-01 00:00:00

  • Challenges in estimating influenza vaccine effectiveness.

    abstract::Introduction: Influenza vaccination is regarded as the most effective way to prevent influenza infection. Due to the rapid genetic changes that influenza viruses undergo, seasonal influenza vaccines must be reformulated and re-administered annually necessitating the evaluation of influenza vaccine effectiveness (VE) e...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2019.1622419

    authors: Ainslie KEC,Haber M,Orenstein WA

    更新日期:2019-06-01 00:00:00

  • Effectiveness, immunogenicity and safety of one vs. two-dose varicella vaccination:a meta-analysis.

    abstract:BACKGROUND:Despite high 1-dose vaccination coverage, breakthrough varicella infections still occur. Therefore, 2-dose vaccination is recommended to enhance the immune response to the virus. However, the reported incremental vaccine effectiveness (VE) of 2-dose vaccination varies widely among studies. METHODS:To determ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/14760584.2018.1433999

    authors: Yin M,Xu X,Liang Y,Ni J

    更新日期:2018-04-01 00:00:00

  • BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control.

    abstract::The bacillus Calmette-Guérin (BCG) vaccine, initially developed to provide protection against TB, also protects against leprosy; and the magnitude of this effect varies. Previous meta-analyses did not provide a summary estimate of the efficacy due to the heterogeneity of the results. We conducted a meta-analysis of pu...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,meta分析

    doi:10.1586/erv.09.161

    authors: Merle CS,Cunha SS,Rodrigues LC

    更新日期:2010-02-01 00:00:00

  • Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.

    abstract::Invasive meningococcal disease is a global public-health concern, with infants and adolescents bearing the majority of the disease burden. Vaccination is the most rational strategy to prevent meningococcal disease. Control of serogroup C disease has largely been achieved by the introduction of glycoconjugate meningoco...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.09.18

    authors: Pace D

    更新日期:2009-05-01 00:00:00

  • Antigen delivery systems.

    abstract::Many vaccine candidates are highly purified, sometimes monomeric antigens and as a result, not very immunogenic. Antigen delivery systems optimize the presentation of antigens. They also play a major role in solving the problem of there being an increasing number of vaccines but limited opportunities in which to inclu...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.3.4.453

    authors: Kersten G,Hirschberg H

    更新日期:2004-08-01 00:00:00

  • Vaccines for lyssaviruses other than rabies.

    abstract::Several new lyssaviruses have emerged in the past decade and it is likely that more remain to be discovered. There are six recognized genotypes of lyssavirus other than the rabies virus (genotype 1). All but one of these has been associated with human cases, with the resulting disease clinically similar to rabies. Rab...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.4.4.533

    authors: Nel LH

    更新日期:2005-08-01 00:00:00

  • Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.

    abstract::Active immunotherapy aimed at the stimulation of tumor-specific T cells has established itself within the clinic as a therapeutic option to treat cancer. One strategy is the use of so-called peptides that mimic genuine T-cell epitopes as vaccines to activate tumor-specific T cells. In various clinical trials, differen...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2014.862499

    authors: Talebian Yazdi M,Keene KR,Hiemstra PS,van der Burg SH

    更新日期:2014-01-01 00:00:00

  • Multimeric-001: BiondVax's universal flu vaccine. Interview by Duc Le.

    abstract::Dr Tamar Ben-Yedidia has more than 15 years of experience in the field of immunology, with specific expertise in the development of vaccines. She started her career with Biotechnology General Ltd (BTG; Rehovot, Israel), working on the development of a recombinant hepatitis B vaccine. She joined the Weizmann Institute ...

    journal_title:Expert review of vaccines

    pub_type: 面试

    doi:10.1586/erv.10.2

    authors: Ben-Yedidia T

    更新日期:2010-03-01 00:00:00

  • Vaccine development for syphilis.

    abstract:INTRODUCTION:Syphilis, caused by the spirochete Treponema pallidum subspecies pallidum, continues to be a globally prevalent disease despite remaining susceptible to penicillin treatment. Syphilis vaccine development is a viable preventative approach that will serve to complement public health-oriented syphilis prevent...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2016.1203262

    authors: Lithgow KV,Cameron CE

    更新日期:2017-01-01 00:00:00

  • Development of Group A streptococcal vaccines: an unmet global health need.

    abstract::Group A Streptococcus (GAS) infections are a significant global cause of morbidity and mortality. GAS diseases disproportionally affect those living in conditions characterized by poverty and social injustice, in both developing countries and in marginalized populations of industrialized nations. In Australia and New ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1116946

    authors: Sheel M,Moreland NJ,Fraser JD,Carapetis J

    更新日期:2016-01-01 00:00:00

  • Phagocytosis of synthetic particulate vaccine delivery systems to program dendritic cells.

    abstract::Therapeutic prospects of particulates are increasingly recognized for vaccination purposes. Compared with biologic particulates, such as live or attenuated bacterial vectors and viral vectors, synthetic particulates may be expected to ease the hurdles of quality assurance and validation in vaccine development and prod...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.1.2.215

    authors: Thiele L,Merkle HP,Walter E

    更新日期:2002-08-01 00:00:00

  • Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.

    abstract::Although mass vaccination of the entire population of an endemic area would be the most cost-effective tool to diminish Leishmania burden, an effective vaccine is not yet commercially available. Practically, vaccines have failed to achieve the required level of protection, possibly owing to the lack of an appropriate ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.166

    authors: Doroud D,Rafati S

    更新日期:2012-01-01 00:00:00

  • Current developments and prospects on human metapneumovirus vaccines.

    abstract:INTRODUCTION:Human metapneumovirus (hMPV) has become one of the major pathogens causing acute respiratory infections (ARI) mainly affecting young children, immunocompromised patients, and the elderly. Currently there are no licensed vaccines against this virus. Areas covered: Since the discovery of hMPV in 2001, many g...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2017.1283223

    authors: Márquez-Escobar VA

    更新日期:2017-05-01 00:00:00

  • Stress and antibody response to vaccination: implications of animal studies for human clinical research.

    abstract::Psychological stress has been shown to be associated with poorer antibody levels following vaccination in both animals and humans, although the mechanisms underlying this relationship remain unclear. However, animal research has enabled investigation of how this relationship may be affected by the influence of individ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.3.2.141

    authors: Burns V

    更新日期:2004-04-01 00:00:00

  • Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity.

    abstract::Influenza inflicts significant global mortality and morbidity that can be combated by effective immunization. However, the protective efficacy of current vaccines is limited by both the significant antigenic diversity of the viral hemagglutinin protein and the capacity for rapid antigenic change. This necessitates glo...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.1068125

    authors: Wheatley AK,Kent SJ

    更新日期:2015-01-01 00:00:00

  • Controlling pertussis: how can we do it? A focus on immunization.

    abstract:INTRODUCTION:Pertussis is a highly contagious disease of the respiratory tract which is caused by the bacterium Bordetella pertussis and is most severe in those <1 year of age. A vaccine against pertussis, introduced in the 1950's, led to a significant decrease in incidence of the disease, but recent increases in outbr...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2018.1445530

    authors: Martinón-Torres F,Heininger U,Thomson A,Wirsing von König CH

    更新日期:2018-04-01 00:00:00